Showing 4411-4420 of 10240 results for "".
- Five-Year Data for Ilumya Show Long-term Efficacy, Safetyhttps://practicaldermatology.com/news/five-year-data-for-ilumya-show-long-term-efficacy-safety/2460698/Long-term data from Phase 3 extension trials for Sun Pharma’s Ilumya (tildrakizumab) in psoriasis show the treatment provided sustained disease control over five years among subjects who were week 28 tildrakizumab responders and etanercept partial responders/nonresponders.
- Breaking Business News: Evolus' Jeuveau Can Stay on U.S. Market For Nowhttps://practicaldermatology.com/news/breaking-business-news-evolus-jeuveau-can-stay-on-us-market-for-now/2460690/Evolus Inc. can remain for sale in the U.S. temporarily while an appeals court re-considers an import ban won by AbbVie Inc.’s Allergan that was slated to go into effect on Feb. 16, 2021, according to
- Soliton's RAP Technology Now Cleared for Cellulitehttps://practicaldermatology.com/news/solitons-rap-technology-now-cleared-for-cellulite/2460681/The FDA has cleared Soliton Inc.’s Rapid Acoustic Pulse (RAP) technology for the short-term improvement in the appearance of cellulite. Harnessing the power of sound, the unique, rapid-pulsed technology safely and comfortably breaks apart the fibrous septa bands beneath the skin that cause
- Bristol Myers Squibb: Positive Topline Results Pivotal Phase 3 Psoriasis Study of Deucravacitinibhttps://practicaldermatology.com/news/bristol-myers-squibb-positive-topline-results-pivotal-phase-3-psoriasis-study-of-deucravacitinib/2460678/Bristol Myers Squibb shared positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib, a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to s
- NRS Survey Finds Rosacea Patients Lack Knowledge of Antibiotic Resistancehttps://practicaldermatology.com/news/nrs-survey-finds-rosacea-patients-lack-knowledge-of-antibiotic-resistance/2460671/A majority of rosacea patients have never heard of antibiotic resistance, results of a recent survey by the National Rosacea Society (NRS) show. Yet topical or oral antibiotics are among the most commonly prescribed treatments for rosacea. The NRS’s rec
- Soliton, US Navy to Collaborate on Study of RAP for Fibrotic Scarshttps://practicaldermatology.com/news/soliton-us-navy-to-collaborate-on-study-of-rap-for-fibrotic-scars/2460670/Soliton, Inc. will collaborate with the US Navy to conduct a multi-treatment proof-of-concept clinical study to evaluate the safety and efficacy of multiple treatments with Soliton's Rapid Acoustic Pulse (RAP) device for the improvement in the appearance of fibrotic scars. The study
- Pulse Biosciences Scores CE Mark for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-ce-mark-for-cellfx-system/2460666/Pulse Biosciences, Inc. received CE mark for the CellFXSystem. The Company can now proceed with its planned controlled launch of the CellFX System to medical practices within the European Union (EU) for the treatment of general dermatologic conditions, including sebaceous hyperplasia (S
- Candela Launches Frax Pro Systemhttps://practicaldermatology.com/news/candela-launches-frax-pro-system/2460665/Candela’s Frax Pro system is now available. This platform features Frax 1550 and the novel Frax 1940 applicators. The Frax 1940 handpiece delivers a 1940 nm wavelength laser beam for a shallow, epidermal approach, with focal reach extending to approximately 200 μm in
- Arcutis Starts Phase 3 Trials of Topical Roflumilast Cream for ADhttps://practicaldermatology.com/news/arcutis-starts-phase-3-trials-of-topical-roflumilast-cream-for-ad/2460654/Arcutis Biotherapeutics, Inc. is starting their pivotal Phase 3 clinical trials evaluating topical roflumilast cream (ARQ-151) as a potential treatment for atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://practicaldermatology.com/news/ajinomoto-bio-pharma-services-and-revance-therapeutics-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2460641/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.